ClinicalTrials.gg
CompletedNCT00056654Updated Sep 17, 2008

Study of a 6-Month Sustained-Release Formulation of Leuprolide Acetate in Prostate Cancer

An interventional study of Leuprolide acetate in Prostatic Neoplasms, sponsored by Abbott. Completed at 55 sites in United States. Open to male participants. Per ClinicalTrials.gov, last updated 2008-09-17.

Sponsored by Abbott · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
164
Allocation
Non-randomized
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 70 studies testing leuprolide in Prostatic Neoplasms — 9 open to participants now, 16 under way, 6 of them phase 3. Leuprolide · Prostatic Neoplasms.

Enrollment
13th of 69
164 · median 77
Started
2003
with 3 others
No phase
5 of 70
1 open now
Registered
4th of 70
by date
Lead sponsor
2 of 70
Abbott

Among the 70 studies testing leuprolide in Prostatic Neoplasms, this one is the 13th largest by enrollment of the 69 interventional ones that give a count, is one of 4 that started in 2003, is one of 5 with no phase, and was the 4th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

9 of the 70 studies testing leuprolide in Prostatic Neoplasms are open now, in 5 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About leuprolide

Leuprolide: first FDA approval 1985 (LUPRON), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing leuprolide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The primary purpose of the study is to determine if a new sustained-release 45 mg (depot) formulation of leuprolide acetate will reduce serum testosterone levels to and maintain them at medically castrate levels in subjects with prostatic adenocarcinoma.

Read the detailed description

The primary purpose of the study is to determine if a new sustained-release 45 mg (depot) formulation of leuprolide acetate administered once every 26 weeks for 1 year, will lower testosterone levels to and maintain them at medically castrate levels in subjects with prostatic adenocarcinoma. This study will also evaluate the pharmacokinetic profile of the 45 mg formulation and assess the safety of this formulation.

03

Conditions studied

  • Prostatic Neoplasms

Browse trials for

Keywords

  • Leuprolide
  • Prostatic Neoplasms
  • Testosterone
  • Prostate-specific Antigen
  • Pharmacokinetics
  • luprolide acetate
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histological diagnosis of prostate cancer
  • Need for androgen deprivation treatment for 1 year
  • Serum testosterone level ≥ 150 ng/dL
  • of at least 18 months
  • Performance status grades 0,1 or 2

Exclusion criteria

Exclusion Criteria:

  • to leuprolide acetate or polylactic acid
  • History of bilateral orchiectomy, adrenalectomy, or hypophysectomy
  • History of hypogonadism
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
164 participants (actual)

Study arms

  • Experimental
    1

    Drug: Leuprolide acetate

Interventions

06

What researchers measure

Primary outcomes

  1. Suppression of serum testosterone (<=50 ng/dL) and maintenance of serum testosterone suppression once suppression is achieved for individual subjects.

    Time frame: Day 32 through Week 52

Secondary outcomes

  1. Change from baseline in Eastern Cooperative Oncology Group (ECOG) performance status.

    Time frame: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 and Final Visit

  2. Change from baseline in symptom severity (bone pain, pain on urination, urination difficulty).

    Time frame: Weeks 1, 4, 8, 12, 16, 20, 24, 26, 27, 28, 30, 32, 36, 40, 44, 48, 52 and Final Visit

  3. Change from baseline in prostate specific antigen (PSA).

    Time frame: Weeks 1, 12, 26, 27, 30, 40, 52 and Final Visit

  4. Change from baseline in prostatic acid phosphatase (PAP).

    Time frame: Weeks 1, 12, 26, 40, 52 and Final Visit

07

Study locations

55 sites
  • Urology Centers of Alabama
    Homewood, Alabama 35209, United States
  • Medical Affiliated Research Center
    Huntsville, Alabama 35801, United States
  • Alaska Clinical Research Center, LLC
    Anchorage, Alaska 99508, United States
  • Arkansas Urology
    Little Rock, Arkansas 72211, United States
  • Pacific Clinical Center
    Encino, California 91316, United States
  • Los Angeles Clinical Research Center
    Encino, California 91416, United States
  • Urology Associates of Central California
    Fresno, California 93720, United States
  • Center for Urologic Research
    La Mesa, California 91942, United States
  • South Orange County Medical Research Center
    Laguna Woods, California 92653, United States
  • San Diego Uro-Research
    San Diego, California 92101, United States
  • Western Clinical Research
    Torrance, California 90505, United States
  • Urology Research Options
    Aurora, Colorado 80012, United States
  • Connecticut Clinical Research Center
    Waterbury, Connecticut 06708, United States
  • South Florida Medical Research
    Aventura, Florida 33180, United States
  • Atlantic Urological Associates
    Daytona Beach, Florida 32114, United States
  • UroSearch
    Inverness, Florida 34452, United States
  • Advanced Research Institute
    New Port Richey, Florida 34652, United States
  • Atlantic Urological Associates
    New Smyrna Beach, Florida 32168, United States
  • UroSearch
    Ocala, Florida 34470, United States
  • Florida Foundation for Healthcare Research
    Ocala, Florida 34474, United States
  • Atlantic Urological Associates
    Orange City, Florida 32763, United States
  • Atlantic Urological Associates
    St. Augustine, Florida 32086, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • Georgia Urology, PA
    Atlanta, Georgia 30342, United States
  • West Side Veteran Administration Medical Center
    Chicago, Illinois 60602, United States
  • Kankakee Urological Associates
    Kankakee, Illinois 60901, United States
  • Specialty Care Research
    Peoria, Illinois 61614, United States
  • Welborn Clinic East
    Evansville, Indiana 47713, United States
  • Northeast Indiana Research
    Fort Wayne, Indiana 46825, United States
  • Urology of Indiana, LLC
    Indianapolis, Indiana 46202, United States
  • Urological Associates, PC
    Davenport, Iowa 52807, United States
  • 206 Research Associates
    Greenbelt, Maryland 20770, United States
  • Lawrenceville Urology
    St Joseph, Michigan 49085, United States
  • Kansas City Urology Care
    Kansas City, Missouri 64111, United States
  • Saint Louis Urological Surgeons, Inc
    St Louis, Missouri 63136, United States
  • Sheldon J. Freedman, MD, LTD
    Las Vegas, Nevada 89109, United States
  • Nevada Urology Associates
    Reno, Nevada 89511, United States
  • Urological Surgical Associates
    Edison, New Jersey 08837, United States
  • Lawrenceville Urology
    Lawrenceville, New Jersey 08648, United States
  • Associated Urologic Specialists, PA
    Marlton, New Jersey 08053, United States
  • Suffolk Urology Associates
    Bay Shore, New York 11706, United States
  • Urological Surgeons of Long Island
    Garden City, New York 11530, United States
  • Hudson Valley Urology
    Poughkeepsie, New York 12601, United States
  • Center for Urologic Research of Western New York
    Williamsville, New York 14221, United States
  • Northeast Urology Research
    Concord, North Carolina 28025, United States
  • The Urology Group
    Cincinnati, Ohio 45212, United States
  • University Urological Research Institute
    Providence, Rhode Island 02906, United States
  • Grand Strand Urology
    Myrtle Beach, South Carolina 29572, United States
  • Vanderbilt Medical Center Dept of Urologic Surgery
    Nashville, Tennessee 37232, United States
  • Urology Specialists & Associates
    Dallas, Texas 75231, United States
  • Urology Associates of North Texas
    Fort Worth, Texas 76104, United States
  • Urology San Antonio Research
    San Antonio, Texas 78229, United States
  • Salt Lake Research
    Salt Lake City, Utah 84124, United States
  • Devine-Tidewater Urology
    Virginia Beach, Virginia 23454, United States
  • Madigan Army Medical Center
    Tacoma, Washington 98431, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2003, a primary completion of Jul 2004 and a completion of Jul 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2003
First posted
Mar 21, 2003
Start
Mar 2003
Primary completionActual
Jul 2004
CompletionActual
Jul 2004
Last update
Sep 17, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00056654
Lead sponsor
Abbott
First posted
Mar 21, 2003
Start date
Mar 2003
Primary completion
Jul 2004
Completion
Jul 2004
Last update
Sep 17, 2008

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Leuprolide

Start the discussion